| Trial ID: | L3856 |
| Source ID: | NCT02046395
|
| Associated Drug: |
Amlodipine, Hydralazine, Terazosin Or Hydrochlorothiazide
|
| Title: |
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
UFLC
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02046395/results
|
| Conditions: |
Type 2 Diabetes|Hypertension
|
| Interventions: |
DRUG: amlodipine, hydralazine, terazosin or hydrochlorothiazide
|
| Outcome Measures: |
Primary: Change in Urine Microalbumin Creatinine Ratio, Kidney function will be assessed throughout the study to assess changes in function prior to the washout of ACE/ARB medication and reintroduction of the ACE/ARB medication., Visit 1 (Baseline), Visit 3 (Day 60) | Secondary: Change in the Level of Urinary Free Light Chains, In relation to kidney function and washout/reintroduction of ACE/ARB medication the level of urinary free light chains will be assessed., Visit 1 (Baseline), Visit 3 (Day 60)
|
| Sponsor/Collaborators: |
Sponsor: Tulane University School of Medicine
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
28
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2012-01
|
| Completion Date: |
2019-12
|
| Results First Posted: |
2023-08-21
|
| Last Update Posted: |
2023-08-21
|
| Locations: |
Tulane University Health Sciences Center, New Orleans, Louisiana, 70112, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02046395
|
